Merck (NYSE: MRK) has announced that its Board of Directors declared a quarterly dividend of $0.85 per share of common stock for the third quarter of 2026. This payment is scheduled for July 8, 2026, to shareholders of record as of June 15, 2026. The company also included a forward-looking statement regarding potential risks and uncertainties that could affect future results.

FMC Corporation announced that its CFO, Andrew Sandifer, will speak at the 16th Annual Wells Fargo Industrials & Materials Conference on June 9, 2026, at 2:15 p.m. Central Time. A live webcast of his presentation will be available for investors. FMC is a global agricultural sciences company providing innovative crop protection solutions to growers.

Gartner warns that the rush to agentic AI in supply chain planning (SCP) organizations carries risks of hype and "agent washing." Most current agentic capabilities improve user experience rather than fundamentally changing decision quality, and true end-to-end autonomous planning is not expected before 2027. SCP leaders should prioritize building operational discipline and flexible frameworks, and avoid common missteps like mistaking vendor positioning for true autonomy or pursuing high-risk autonomous use cases too early.

PG&E Corporation director John O. Larsen received an equity award of 10,948 Restricted Stock Units (RSUs) on May 21, 2026, granted under the company's 2021 Long Term Incentive Plan. These RSUs are valued at $0.00 per share and are payable in common stock on a one-for-one basis upon vesting. Following this and other dividend reinvestment acquisitions, Larsen's direct holdings now total 29,123.45 shares.

Cboe Global Markets, Inc. announced the hiring of Boudewijn Duinstra as Executive Vice President and Chief Risk Officer. Duinstra brings over 30 years of experience in risk management and derivatives markets, previously serving as CEO of ABN AMRO Clearing USA LLC. His appointment comes as Cboe shares are trading at a 52-week high, with the company maintaining a strong financial health score and a history of dividend increases.

Barclays has maintained an "Overweight" rating for Centene (CNC) and raised its price target to $75 from $63, signaling increased confidence in the healthcare company's future. GuruFocus assesses CNC as 31.2% undervalued, with a GF Score™ of 71/100, highlighting strong profitability and valuation despite concerns about growth potential. Insiders have shown a neutral stance with no reported buy or sell transactions in the past three months.

FMC Corporation announced that executive vice president and CFO Andrew Sandifer will speak at the 16th Annual Wells Fargo Industrials & Materials Conference on June 9, 2026, at 2:15 p.m. Central Time. A live webcast of his presentation will be available on FMC's investor relations website. This appearance will provide an opportunity for FMC to discuss its strategy and recent developments with investors, including Q1 2026 results and the India business divestiture.

Synopsys (SNPS) is presented as a "growth trap" despite a 65.5% revenue rise in Q1 FY26, as GAAP operating income fell 19.4% and net income collapsed 78%. The article highlights that Synopsys trades at a high multiple (83x earnings) uncharacteristic of its mid-teens growth, especially as its Design IP revenue declined due to hyperscalers developing proprietary IP. The author argues that without a dividend, mature growth for an AI-priced multiple, and pending a GAAP recovery, the stock's risk/reward profile is unattractive.

Congressman Thomas Kean Jr. sold shares of Take-Two Interactive (NASDAQ: TTWO) and other stocks in April. His sale of Take-Two stock, made before the highly anticipated "GTA VI" release on November 19, 2026, was profitable, yielding an estimated 110.7% return. Despite the sale, the upcoming game release is seen as a major catalyst for Take-Two, with analysts projecting significant upside for its stock.

Gilead Sciences has received approval for its hepatitis D drug, positioning itself against two Bay Area rivals, Vir Biotechnology and Mirum Pharmaceuticals, who are also developing treatments for the severe liver disease. Approximately 60,000 Americans are affected by the most severe form of hepatitis D, making this a significant market for the companies involved.